Advances in Oncology

Expert oncologists at New York’s #1 hospital lead the way in genomics and precision medicine based therapies.

As one of 50 NCI designated comprehensive cancer centers in the country, our oncology program has a proven track record of helping patients beat the odds with comprehensive, coordinated care.

image of 2020 innovations in review cover
2020 Innovations in Review


The Report on Clinical and Scientific Innovations in Oncology highlights the work of NewYork-Presbyterian physicians and scientists in lung and genitourinary cancers, mantle cell lymphoma, myeloma, and glioblastoma.

image of Dr. Nasser Altorki and Dr. Silvia Formenti

Lung Cancer: Testing a Novel Protocol

Combining immune checkpoint blockade and radiotherapy preoperatively is associated with a significant enhancement of major pathological response in the treatment of early-stage non-small-cell lung cancer.

image of Diffuse large B-cell lymphoma

New Understanding of B-Cell Cancers

Weill Cornell Medicine and Columbia University faculty at NewYork-Presbyterian Hospital have uncovered new information on the roles of the microenvironment and genomic architecture underlying the development and progression of B-cell and other malignancies.

image of DNA strand and cancer cell oncology research concept 3D rendering

Novel Approaches to Personalizing Cancer Therapy

Scientists at Columbia University and Weill Cornell Medicine are applying contemporary methods of data analysis to generate algorithms that narrow the number of genetic drivers involved in cancer development.

image of a microscopic section immunostain

Accelerating Therapies for Challenging Blood Disorders

From studies in the laboratory to evaluating therapeutics in clinical trials, faculty at the NCI-designated Herbert Irving Comprehensive Cancer Center at Columbia University and the Weill Cornell Medicine Meyer Cancer Center in partnership with NewYork-Presbyterian are addressing the treatment challenges of blood disorders.

x-ray images of prostate cancer

Prolonging Life for Men with Prostate Cancer

Extending survival was the focus of a recent multinational phase 3 clinical trial of a combination therapy for men with nonmetastatic, castration-resistant prostate cancer. Led by Weill Cornell Medicine Oncology, the study provides evidence that adding androgen-receptor inhibitors to current therapies delays metastasis and improves survival.

digital medical illustration of lung cancer in the lungs

Non-Small Cell Lung Cancer: A New Combination for Neoadjuvant Therapy

A novel trial of chemotherapy combined with a PD-L1 inhibitor administered preoperatively in patients with resectable non-small cell lung cancer has had impressive results, raising expectations among oncologists and surgeons that they may soon have a new therapeutic strategy to offer patients with this life-threatening disease.

vector image of lymphomagenesis

Novel Research Advancing Cancer Care and Treatment

Studies by Columbia University and Weill Cornell Medicine faculty are making headlines in oncology research, providing promising evidence for new therapies and better understanding of the origins of blood and solid tumor cancers.

photomicrograph of a diffuse large B-cell lymphoma (DLBCL)

Extending the Boundaries of Cancer Care

NewYork-Presbyterian/Weill Cornell Medical Center is taking cancer care to the next level. Our healthcare providers are available to treat patients with advanced treatments like CAR T-cell therapy and provide access to clinical trials of promising new and innovative therapies.

image of Fibrosarcoma, light micrograph, photo under microscope

Exceptional Expertise in Rare Cancers

Combined rare cancers account for 50% of all cancer diagnoses. Researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center are leading initiatives in rare cancers for cooperative study groups.

image of cancer cell

Investigating Immunotherapy Approaches in Genitourinary Oncology

Dr. Charles G. Drake initiated a cutting-edge trial in which androgen deprivation therapy is combined with a drug aimed at preventing suppressive myeloid cells from entering the prostate tumor microenvironment at the time of therapy.

image of Vitamin C, DHA conversion, and transport in KRAS and BRAF mutated cells

Confronting Solid Tumors: Vitamin C Takes on the KRAS Gene

With a multimillion dollar grant, investigators at NewYork-Presbyterian/Weill Cornell are conducting human trials to confirm that high doses of vitamin C impairs the growth of colorectal tumors.

image of Dr. Eleni Andreopoulou

Neoadjuvant Therapy in Breast Cancer: A New Raison D’être

In the past 50 years, use of neoadjuvant chemotherapy for breast cancer has evolved. Today, clinicians at NewYork-Presbyterian are using neoadjuvant therapy to tackle residual tumor.

image of Dr. Markus Y. Mapara

A New Take on BMT and Cellular Therapies

As the Adult Blood and Marrow Transplant Program at NewYork-Presbyterian/Columbia continues to expand, clinicians are investigating new treatment approaches ranging from autologous to allogeneic and haplo-identical transplantation.

image of cryotherapy to freeze a tumor

Targeting Early Breast Cancers with Ablation Therapies

Surgeons at NewYork-Presbyterian/Columbia are turning up the heat (or cold as the case may be) on early-stage breast cancer tumors with the use of ablation therapies.

Newsletters for Medical Professionals

2021 Issue 3

2021 Issue 2

2021 Issue 1

2020 Issue 1

2019 Issue 2

2019 Issue 1

2018 Issue 3

2018 Issue 2

2018 Issue 1

2017 Issue 2

2017 Issue 1

Spring/Summer 2016

Fall/Winter 2015

Spring 2015

November/December 2014

September 2014

January 2014

February 2013

January 2013